How to choose between Asciminib and Orebatinib

Asciminib (Asciminib) and olverembatinib (Olverembatinib) are both targeted drugs used to treat chronic myelogenous leukemia (CML). Which drug to choose needs to consider the patient's specific situation, such as the condition, type of gene mutation, previous treatment, etc. The patient's response to and tolerance of the drug also needs to be considered. If one drug doesn't work well or the patient can't tolerate its side effects, the doctor may recommend that the patient try another drug.

Aximini is a kinase inhibitor targeting theBCR-ABL fusion gene. It is mainly used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML). It inhibits BCR-ABL kinase activity and prevents tumor cell proliferation, thereby achieving the effect of treating leukemia. Orebatinib is a kinase inhibitor that mainly targets the T315I mutated BCR-ABL fusion gene and is mainly used to treat drug-resistant chronic myelogenous leukemia (CML). This drug inhibits the activity of BCR-ABL kinase and prevents tumor cell proliferation, thereby achieving the effect of treating leukemia. If the patient's leukemia cells express the BCR-ABL fusion gene, Asiminib can be chosen for treatment.

The original drug of Asiminib has not yet been launched in China, so it cannot be included in medical insurance. The original drug of Asiminil sold overseas is very expensive, and the price of 20mg*60 oral tablets is about more than 20,000 US dollars (the price may fluctuate due to the exchange rate). There are also Assimini generic drugs produced and marketed overseas, and their drug ingredients are basically the same as those of the original drug. For example, the price of 40mg*60 tablets produced by a Laos pharmaceutical factory may be more than 4,000 yuan per box (the price may fluctuate due to exchange rates). The price is relatively cheap. For more information about overseas drugs and specific prices, please consult Yaode Medical Consultant.